BioMedNewsBreaks – GT Biopharma (NASDAQ: GTBP) Releases Q4, Year-End Results, Company Update

April 19, 2021 14:18:30

GT Biopharma (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the company’s proprietary natural killer (“NK”) cell engager, TriKE(TM) protein biologic technology platform, has released fourth-quarter and year-end financial and company results for the period ended Dec. 31, 2020. Company highlights noted in the announcement included entering into a GMP manufacturing partnership with Cytovance; the initiation of manufacturing of additional solid tumor TriKE for lung, breast, ovarian and gastrointestinal cancer programs in preparation for FDA clinical trials; and enhancing and expanding the company’s board of directors. In addition, the company completed a successful listing on NASDAQ and closed on a $28.7 million public offering, which resulted in GT Biopharma having more than $30 million in the bank. “2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, which allowed us to accomplish a major corporate milestone in listing GT Biopharma on NASDAQ at the beginning of 2021,” said GT Biopharma chair and CEO Anthony J. Cataldo in the press release. “The emerging data from our GTB-3550 TriKE program in hematological malignancies, MDS and AML, are encouraging in both safety and efficacy profiles. The ongoing data profile has demonstrated significant differences from all other NK cell therapies and NK engager companies, making TriKE a monotherapy, off-the-shelf platform therapeutic. TriKE exerts its therapeutic effect without the need for outside assistance in the form of combination therapies or the addition of supplemental progenitor-derived or autologous/allogenic NK cells.  As a result, TriKE therapy cost to patients will be far superior, significantly more economic than progenitor-derived or autologous/allogenic NK cell therapy companies’ offerings. Additionally, the results generated from the GTB-3550 TriKE clinical trial reinforces its versatility, providing a clear rationale to proceed with additional programs in solid tumor and hematologic cancers.”

To view the full press release, visit

About GT Biopharma Inc.

GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE NK cell engager platform. The company’s TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. For more information, please visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork